In a reported case of advanced metastatic gastric cancer, complete tumor regression lasting up to 25 months was achieved following initial treatment with a personalized neoantigen-loaded monocyte-derived dendritic cell vaccine (Neo-MoDC) combined with PD - 1 blockade. This represents the first successful case of such therapy in gastric cancer. Here, RPL17 is linked to neoplasm.